1. Home
  2. WIW vs MRVI Comparison

WIW vs MRVI Comparison

Compare WIW & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Opportunities & Income Fund

WIW

Western Asset Inflation-Linked Opportunities & Income Fund

HOLD

Current Price

$8.75

Market Cap

540.9M

Sector

Finance

ML Signal

HOLD

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$3.44

Market Cap

449.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIW
MRVI
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
540.9M
449.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WIW
MRVI
Price
$8.75
$3.44
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$4.54
AVG Volume (30 Days)
229.9K
1.5M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
11.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$192,435,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$1.67
52 Week High
$9.37
$6.21

Technical Indicators

Market Signals
Indicator
WIW
MRVI
Relative Strength Index (RSI) 43.51 51.90
Support Level $8.63 $3.32
Resistance Level $8.87 $3.76
Average True Range (ATR) 0.08 0.22
MACD 0.00 -0.01
Stochastic Oscillator 40.98 42.86

Price Performance

Historical Comparison
WIW
MRVI

About WIW Western Asset Inflation-Linked Opportunities & Income Fund

Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: